Replies to post #137332 on Biotech Values

[mcbio]

This is not true. Most of the targets big pharma working on are at very early stage (Discovery stage). I know for sure that more than 15 different targets are being worked on currently.

Some of them are: CCR2 antagonists, GDIR (or GPR119) agonists, GPR120, GPR140, peripheral CB1, etc,.

Any comments on a glucokinase activator for T2D? ARRY has one of these in Phase 2 via their partnership with AMGN.

[iwfal]

T2D New MOAs -

This is not true. Most of the targets big pharma working on are at very early stage (Discovery stage). I know for sure that more than 15 different targets are being worked on currently.

Some of them are: CCR2 antagonists, GDIR (or GPR119) agonists, GPR120, GPR140, peripheral CB1, etc,.

The probelm with these targets are, they show very good potency and efficacy in preclinical species, but in clinic they are all duds.

Tx - where are you going to see:

a) That preclinical pipeline data - is there some particularly good summary somewhere? Some conference or journal somewhere?

b) The results from those drugs when taken into ph i/ii?

For cancer you can find almost anything in ASCO - but I obviously haven't found the secret source for T2D.